Zentalis Pharmaceuticals, Inc. (ZNTL)
| Market Cap | 3.59B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -179.33M |
| Shares Out | 40.74M |
| EPS (ttm) | -4.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 69,215 |
| Open | 77.13 |
| Previous Close | 77.23 |
| Day's Range | 76.05 - 78.93 |
| 52-Week Range | 34.48 - 81.40 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 85.11 (+8.3%) |
| Est. Earnings Date | Nov 8, 2021 |
About ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical tri...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ZNTL stock is "Strong Buy." The 12-month stock price forecast is 85.11, which is an increase of 8.31% from the latest price.
News
Zentalis Pharmaceuticals Announces First Patient Dosed in the Phase 1/2 Study of ZN-c3 in Combination with Gemcitabin...
Initial results are expected in 2H 2022 Initial results are expected in 2H 2022
Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of it...
NEW YORK and SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule ...
Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
Reported promising new interim data on both ZN-c3 and ZN-c5, highlighting their potentially best-in-class profiles
Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patien...
NEW YORK and SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...
Zentera Therapeutics Announces Closing of $75 Million Series B Financing
Proceeds will be used to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China Proceeds will be used to...
Zentalis Pharmaceuticals Announces Closing of Offering of Common Stock and Full Exercise of Underwriters' Option to P...
NEW YORK and SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...
Zentalis Secures $150M In Equity Funding
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) priced an underwritten public offering of 3.1 million shares at $48.50 per share, for gross proceeds of approximately $150.4 million. The stock's last close p...
Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock
NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...
Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock
NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...
Lengo Therapeutics Appoints Enoch K. Kariuki as Chief Executive Officer
SAN DIEGO--(BUSINESS WIRE)-- #LengoTx--Lengo Therapeutics, a biopharmaceutical company developing novel precision medicines targeting driver mutations in oncology, today announced the appointment of Eno...
Zentalis Pharmaceuticals to Participate in the Jefferies Virtual Healthcare Conference
NEW YORK and SAN DIEGO, May 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule th...
Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update
Reported robust initial results from the Phase 1 monotherapy dose escalation trial of its WEE1 inhibitor, ZN-c3, demonstrating single-agent activity and Exceptional Responses in heavily pre-treated pati...
Zentalis's Early WEE1 Inhibitor Data Shows 'Exceptional' Response In Solid Tumor Study, Plans Combination Trials
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) has announced initial efficacy and safety data from the Phase 1 dose-escalation portion of its ongoing Phase 1/2 trial evaluating ZN-c3 in patients with advan...
Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its...
ZN-c3 is currently being evaluated in patients with advanced solid tumors and ovarian cancer ZN-c3 is currently being evaluated in patients with advanced solid tumors and ovarian cancer
Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its ...
ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumors
Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update
Initiated multiple early-stage clinical trials evaluating its oral SERD, ZN-c5, WEE1 inhibitor, ZN-c3 and BCL-2 inhibitor, ZN-d5
Zentalis Pharmaceuticals Announces Late-Breaker Oral Presentation on WEE1 Inhibitor, ZN-c3, at the AACR Annual Meetin...
Additional preclinical data on ZN-c3 and the Company's EGFR inhibitor, ZN-e4, will be presented as poster presentations Additional preclinical data on ZN-c3 and the Company's EGFR inhibitor, ZN-e4, will...
Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN-c3 at the AACR Annual Meeting 2021
NEW YORK and SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...
Zentalis Pharmaceuticals Announces the Appointment of Dr. Enoch Kariuki to its Board of Directors
NEW YORK & SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule the...
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
NEW YORK and SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...
Why Earnings Season Could Be Great for Zentalis (ZNTL)
Zentalis (ZNTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Andreas Halvorsen Pulls Back Zentalis Pharmaceuticals Holding
Andreas Halvorsen (Trades, Portfolio) has revealed a reduction in his holding of Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL), according to GuruFocus' Real-Time Picks, a Premium feature.
Zentalis Pharmaceuticals to Participate In Two Upcoming Investor Conferences
NEW YORK and SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...
Zentalis Pharmaceuticals to Host a Key Opinion Leader Virtual Meeting to Discuss its Investigational WEE1 Inhibitor Z...
Live webcast to be held on September 24th at 12:00 p.m. EDT Live webcast to be held on September 24th at 12:00 p.m. EDT
Zentalis Pharmaceuticals Appoints Alexis Pinto as Chief Legal Officer
NEW YORK and SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecul...